Silence Therapeutics (SLN) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.15
- EPS estimate
- −$0.19
- EPS surprise
- +19.83%
- Revenue surprise
- −96.37%
- Revenue
- $159,000.00
- Revenue estimate
- $4.4M
- Reported
- Nov 6, 2025
Silence Therapeutics reported Q3 2025 results on November 6, 2025. It posted a loss of $0.15 per share, narrower than the $0.19 loss expected, a beat of 19.83%. Revenue was $159,000 against a $4.4 million estimate, a miss of 96.37%. In Q3 2024 the loss was $0.24 per share on $1.5 million of revenue, so the loss narrowed by 37.5% while revenue fell about 89%.
The table covers 14 quarters from Q1 2022 and has no Q4 2024 row. Silence posted a loss in 13 of them. The exception was Q4 2022, with earnings of $0.45 per share on $17.8 million of revenue, the highest revenue in the table. For the two full years shown, EPS added up to $0.10 in 2022 and a loss of $0.49 in 2023. All three 2025 quarters had revenue below $250,000. Silence beat the EPS estimate 9 times out of 14, but missed in five of the six quarters from Q4 2023 to Q2 2025.
The table holds no results after Q3 2025. In earlier years Silence reported fourth-quarter results in mid-March. The next report will show whether revenue moves back toward 2022 and 2023 levels.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 6, 2025 | −$0.19 | −$0.15 | +19.83% | $159,000.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.13 | −$0.19 | −43.40% | $224,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.15 | −$0.20 | −32.63% | $142,000.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.13 | −$0.24 | −90.35% | $1.5M | SEC |
| Q2 2024 | Aug 15, 2024 | −$0.11 | −$0.14 | −25.18% | $768,579.00 | SEC |
| Q1 2024 | May 16, 2024 | −$0.12 | −$0.02 | +85.29% | $15.7M | SEC |
| Q4 2023 | Mar 13, 2024 | −$0.08 | −$0.16 | −98.38% | $2.7M | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.17 | −$0.09 | +46.36% | $3.5M | SEC |
| Q2 2023 | Aug 16, 2023 | −$0.17 | −$0.12 | +29.21% | $11.6M | SEC |
| Q1 2023 | May 16, 2023 | −$0.15 | −$0.12 | +21.28% | $14.2M | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.01 | $0.45 | +3748.39% | $17.8M | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.20 | −$0.08 | +58.18% | $3.9M | — |
| Q2 2022 | Aug 11, 2022 | −$0.20 | −$0.16 | +19.84% | $4.3M | — |
| Q1 2022 | May 16, 2022 | −$0.19 | −$0.11 | +44.76% | $7.0M | — |
Quarterly revenue
Frequently asked questions
When did Silence Therapeutics (SLN) last report earnings?
Silence Therapeutics last reported on Nov 6, 2025, covering fiscal Q3 2025.
Did SLN beat earnings estimates?
Yes. Silence Therapeutics reported EPS of −$0.15 for Q3 2025 against a −$0.19 estimate — a 19.83% beat.
How much revenue did SLN report last quarter?
Silence Therapeutics reported $159,000.00 in revenue for Q3 2025, against a consensus estimate of $4.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.